By Ketaki Gokhale and Makiko Kitamura / Bloomberg News
March 8, 2015 11:27 PM
MUMBAI, India — A $10 version of Sovaldi, the Gilead Sciences Inc. hepatitis C treatment that sells for $1,000 a pill in the U.S., is now available in Bangladesh and could make its way to other parts of the world where the U.S. company doesn’t have patents.
Incepta Pharmaceuticals Ltd. doesn’t have a license from Gilead and its version was launched last month, said managing director Abdul Muktadir. The company also aims to sell the drug overseas, including to parts of Southeast Asia and Africa.
So wrong once again AMERICANS get SCREWED!!!!!!!!!!!!
ReplyDelete